TriSalus Life Sciences Announces Strong Q2 2025 Results, Affirms Full-Year Outlook, and Advances Strategic Focus on Liver-Directed Therapies TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company pioneering innovative delivery solutions for treating solid tumors, today reported its financial results…
Bayer and Kumquat Biosciences Forge Global Exclusive Agreement to Advance Next-Generation KRAS G12D Inhibitor in Precision Oncology Bayer AG, a global life sciences company with a growing presence in oncology, and Kumquat Biosciences Inc., a clinical-stage biotechnology company founded by…
Laxxon Medical Achieves Major Product Development Milestone with Novel SPID®-Based Oral Modified-Release Formulation of Veru’s Enobosarm Laxxon Medical Corp., a pioneering pharmaceutical technology company specializing in next-generation oral drug delivery systems, announced a significant advancement in its collaboration with Veru…
Thermo Fisher Scientific Secures FDA Approval for NGS-Based Companion Diagnostic to Support New HER2-Targeted NSCLC Therapy Thermo Fisher Scientific Inc. (NYSE: TMO), the global leader in serving science, has announced a significant regulatory milestone with the U.S. Food and Drug…
Newron Announces Landmark Preclinical Study Supporting Evenamide’s Potential to Transform Schizophrenia Treatment Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases of the central and peripheral nervous system, has highlighted…
CGT Global Strengthens Advisory Leadership with Appointment of Dr. Andrew Branagan, Enhancing Expertise in Hematologic Malignancies and Advanced Cell and Gene Therapy Development CGT Global, a biotechnology innovator dedicated to advancing the development, manufacturing, and delivery of cutting-edge cell and…
Precision BioSciences Reports Second Quarter 2025 Financial Results, Highlights Strong Clinical Progress in Gene Editing Programs, and Extends Cash Runway Into 2027 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company harnessing its proprietary ARCUS® genome editing platform to develop…
WuXi Biologics Earns Coveted Spot on CDP’s Supplier Engagement A List, Strengthening Its Position as a Global ESG Leader WuXi Biologics (2269.HK), a globally renowned Contract Research, Development, and Manufacturing Organization (CRDMO), has once again underscored its commitment to sustainability…
Promega and Aobious Reach Comprehensive Settlement in Patent Infringement Lawsuit Over Bioluminescent Technology Promega Corporation and Aobious Inc. have officially concluded a contentious legal battle over bioluminescent reagent patents, reaching a settlement agreement that addresses a lawsuit involving proprietary furimazine…
Kashiv BioSciences and MS Pharma Forge Strategic Alliance to Bring XOLAIR® Biosimilar ADL-018 to MENA Region Kashiv BioSciences, LLC, a U.S.-based biopharmaceutical company specializing in complex generics and biosimilars, and MS Pharma, a leading pharmaceutical company in the Middle East…
Genmab Appoints Dr. Katja Nielsen as General Manager for Germany, Strengthening European Commercial Expansion Genmab A/S (Nasdaq Copenhagen: GMAB), a global biotechnology leader in antibody-based medicines for cancer and other serious diseases, today announced the appointment of Dr. Katja Nielsen…
European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies, has reached another significant milestone. On July 21, the European…